Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2009138792) SUBSTITUTED QUINAZOLINES
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2009/138792 International Application No.: PCT/GB2009/050512
Publication Date: 19.11.2009 International Filing Date: 13.05.2009
Chapter 2 Demand Filed: 24.02.2010
IPC:
C07D 471/04 (2006.01) ,C07D 475/04 (2006.01) ,C07D 491/048 (2006.01) ,C07D 495/04 (2006.01) ,A61K 31/519 (2006.01) ,A61P 7/02 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
471
Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
475
Heterocyclic compounds containing pteridine ring systems
02
with an oxygen atom directly attached in position 4
04
with a nitrogen atom directly attached in position 2
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
491
Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/-C07D459/290
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
044
with only one oxygen atom as ring hetero atom in the oxygen-containing ring
048
the oxygen-containing ring being five-membered
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
495
Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
33
Heterocyclic compounds
395
having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
495
having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519
ortho- or peri-condensed with heterocyclic rings
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7
Drugs for disorders of the blood or the extracellular fluid
02
Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Applicants:
GOLDING, Bernard [GB/GB]; GB (UsOnly)
CICALA, Peter [US/US]; US (UsOnly)
FRANKLIN, Richard [GB/GB]; GB (UsOnly)
HIRST, Kim [GB/GB]; GB (UsOnly)
SHIRE LLC [US/US]; 9200 Brookfield Court Florence, Kentucky 41042, US (AllExceptUS)
Inventors:
GOLDING, Bernard; GB
CICALA, Peter; US
FRANKLIN, Richard; GB
HIRST, Kim; GB
Agent:
HARRISON GODDARD FOOTE; Belgrave Hall Belgrave Street Leeds West Yorkshire LS2 8DD, GB
Priority Data:
0808951.816.05.2008GB
Title (EN) SUBSTITUTED QUINAZOLINES
(FR) QUINAZOLINES SUBSTITUÉES
Abstract:
(EN) This invention relates to the discovery of 3-and 5-substituted analogues of the selective platelet lowering agent anagrelide with reduced potential for cardiovascular side-effects which should lead to improved patient compliance and safety in the treatment of myeloproliferative diseases. More specifically, the present invention relates to certain imidazoquinazoline derivatives which have the general formula shown below wherein the substituents have the meanings defined in claim 1: and which have utility as platelet lowering agents in humans. The compounds of the present invention function by inhibiting megakaryocytopoeisis and hence the formation of blood platelets.
(FR) L'invention concerne la découverte d'analogues substitués en position 3 et 5 de l'anagrélide, un agent de réduction sélective du nombre des plaquettes, présentant un potentiel réduit d'effets secondaires cardiovasculaires et qui devraient conduire à une observance thérapeutique et à une sécurité améliorées dans le traitement de syndromes myéloprolifératifs. Plus spécifiquement, la présente invention concerne certains dérivés d'imidazoquinazoline représentés par la formule générale décrite ci-dessous, dans laquelle les substituants présentent les significations définies dans la revendication 1, et qui présentent une utilité en tant qu'agents de réduction du nombre des plaquettes chez les êtres humains. Les composés de la présente invention agissent en inhibant la mégacaryocytopoïèse et par conséquent la formation des plaquettes sanguines.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)